Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
November 09, 2017 08:28 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change

Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 millionCompany Announces Leadership Change and Search for Chief Executive Officer VANCOUVER, British Columbia, Nov. 09, 2017 ...
October 31, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer

VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
October 12, 2017 09:15 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D

VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
September 24, 2017 08:00 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
September 15, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
September 11, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors

VANCOUVER, British Columbia, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
August 08, 2017 07:00 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Reports Second Quarter 2017 Financial Results

MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time AdjustmentsGlobal Expansion Plans for Metreleptin Opportunity UnderwayCompany Updates Guidance for FY 2017 Total Net...
August 02, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors

VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
July 28, 2017 08:30 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017

VANCOUVER, British Columbia, July 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right